These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9777746)

  • 41. Discriminant factors affecting early outcome of radioiodine treatment for Graves' disease.
    Kung AW; Choi P; Lam KS; Pun KK; Wang C; Yeung RT
    Clin Radiol; 1990 Jul; 42(1):52-4. PubMed ID: 2390837
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Analysis of ¹³¹I therapy and correlation factors of Graves' disease patients: a 4-year retrospective study.
    Zheng W; Jian T; Guizhi Z; Zhaowei M; Renfei W
    Nucl Med Commun; 2012 Jan; 33(1):97-101. PubMed ID: 22008631
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A thermoluminescent method for the evaluation of the
    Meftah S; Kraiem T
    Radiat Environ Biophys; 2021 May; 60(2):289-298. PubMed ID: 33797646
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Radioiodine versus surgery in the treatment of Graves' hyperthyroidism].
    Jukić T; Stanicić J; Petric V; Kusić Z
    Lijec Vjesn; 2010; 132(11-12):355-60. PubMed ID: 21294325
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A study of the possibility of curing Graves' disease based on the desired reduction of thyroid mass (volume) as a consequence of 131I therapy: a speculative paper.
    Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
    Nucl Med Commun; 2006 May; 27(5):439-46. PubMed ID: 16609355
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry?
    Eschner W; Kobe C; Schicha H
    Z Med Phys; 2011 Dec; 21(4):258-65. PubMed ID: 21719262
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Graves' disease and radioiodine therapy. Is success of ablation dependent on the achieved dose above 200 Gy?
    Kobe C; Eschner W; Sudbrock F; Weber I; Marx K; Dietlein M; Schicha H
    Nuklearmedizin; 2008; 47(1):13-7. PubMed ID: 18278207
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves' disease.
    Nakazato N; Yoshida K; Mori K; Kiso Y; Sayama N; Tani JI; Nakagawa Y; Ito S
    Thyroid; 1999 Aug; 9(8):775-9. PubMed ID: 10482369
    [TBL] [Abstract][Full Text] [Related]  

  • 49. International differences in approaches to 131I therapy for Graves' disease: case selection and restrictions recommended to patients in Japan, Korea, and China.
    Tominaga T; Yokoyama N; Nagataki S; Cho BY; Koh CS; Chen JL; Shi Y
    Thyroid; 1997 Apr; 7(2):217-20. PubMed ID: 9133688
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differences in Brain Glucose Metabolism During Preparation for
    Jeong HS; Choi EK; Song IU; Chung YA; Park JS; Oh JK
    Thyroid; 2017 Jan; 27(1):23-28. PubMed ID: 27774839
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Determining thyroid (131)I effective half-life for the treatment planning of Graves' disease.
    Willegaignon J; Sapienza MT; Coura Filho GB; Traino AC; Buchpiguel CA
    Med Phys; 2013 Feb; 40(2):022502. PubMed ID: 23387769
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of methods for thyroid volume estimation in patients with Graves' disease.
    van Isselt JW; de Klerk JM; van Rijk PP; van Gils AP; Polman LJ; Kamphuis C; Meijer R; Beekman FJ
    Eur J Nucl Med Mol Imaging; 2003 Apr; 30(4):525-31. PubMed ID: 12541136
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Calculation of therapeutic activity of radioiodine in Graves' disease by means of Marinelli's formula, using technetium (
    Szumowski P; Mojsak M; Abdelrazek S; Sykała M; Amelian-Fiłonowicz A; Jurgilewicz D; Myśliwiec J
    Endocrine; 2016 Dec; 54(3):751-756. PubMed ID: 27553050
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fibroblast growth factor-2 free from extracellular matrix is increased in papillary thyroid carcinomas and Graves' thyroids.
    Emoto N; Onose H; Sugihara H; Minami S; Shimizu K; Wakabayashi I
    Thyroid; 1998 Jun; 8(6):491-7. PubMed ID: 9669286
    [TBL] [Abstract][Full Text] [Related]  

  • 55. First reported case of unilateral Graves' disease in the left lobe of a bilobar thyroid gland.
    Chen LC; Green JB
    Thyroid; 2011 Jun; 21(6):683-6. PubMed ID: 21563918
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Graves' disease in the cervical thyroid and thyroglossal duct remnant: case report and review of literature.
    Buckingham H; Sauerwein TJ; Golding AC
    Endocr Pract; 2006; 12(4):401-5. PubMed ID: 16901795
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Positron emission tomography reveals correlations between brain metabolism and mood changes in hyperthyroidism.
    Schreckenberger MF; Egle UT; Drecker S; Buchholz HG; Weber MM; Bartenstein P; Kahaly GJ
    J Clin Endocrinol Metab; 2006 Dec; 91(12):4786-91. PubMed ID: 16968792
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tissue calmodulin levels in normal and Graves' thyroids.
    Inaba M; Hamada N; Morii H; Nishizawa Y; Yamakawa J; Ohno M; Tsuda S; No J; Kanayama Y; Saitoh H
    Endocrinol Jpn; 1984 Dec; 31(6):711-7. PubMed ID: 6398218
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Clinical use of nuclear medicine in the management of thyroid diseases].
    Endo K
    Nihon Rinsho; 2007 Nov; 65(11):2009-15. PubMed ID: 18018563
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Increased insulin-like growth factor-1 receptors in thyroid tissues of Graves' disease.
    Hsiao PJ; Tsai JH
    J Formos Med Assoc; 1994; 93(11-12):925-32. PubMed ID: 7633196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.